Article
Biochemistry & Molecular Biology
Barbara Vizio, Ornella Bosco, Ezio David, Gian Paolo Caviglia, Maria Lorena Abate, Martina Schiavello, Angela Pucci, Antonina Smedile, Gianluca Paraluppi, Renato Romagnoli, Enrico Lupia, Graziella Bellone, Giuseppe Montrucchio
Summary: The study revealed that THPO and VEGF-A expression levels were significantly elevated in tumor tissues compared to liver cirrhosis tissues in HCC patients. There was a linear correlation between THPO and VEGF-A transcripts in HCC, indicating a potential interdependent regulation between the two growth factors in promoting cellular growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Yuan Lin, Meng-Qi Dong, Zhi-Min Liu, Meng Xu, Zhi-Hao Huang, Hong-Juan Liu, Yi Gao, Wei-Jie Zhou
Summary: There are currently no effective treatments for liver fibrosis, a disease that involves angiogenesis. The role of different microvessels in the liver during fibrogenesis is unclear, and it is difficult to treat liver fibrosis through vascular targeting. This study proposes a combined regulation of multiple different endothelial cell regulatory signaling pathways as a new strategy for liver fibrosis therapy.
Review
Cell Biology
Sophia Daum, Hannes Hagen, Erin Naismith, Dominik Wolf, Andreas Pircher
Summary: Tumor progression relies heavily on vascular supply, with inhibition of angiogenesis being a promising therapeutic strategy. Recent advancements in single cell RNA sequencing and preclinical observations allow for detailed characterization of the tumor microenvironment in NSCLC, leading to the identification of new aspects for personalized inhibition of angiogenesis. The tumor vasculature consists of various cellular subtypes that interact closely with other components of the tumor microenvironment, providing insight for the development of more targeted combinational therapies in NSCLC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Yanxia Li, Nelusha Amaladas, Marguerita O'Mahony, Jason R. Manro, Ivan Inigo, Qi Li, Erik R. Rasmussen, Manisha Brahmachary, Thompson N. Doman, Gerald Hall, Michael Kalos, Ruslan Novosiadly, Oscar Puig, Bronislaw Pytowski, David A. Schaer
Summary: Combined blockade of VEGFR-2 and PD-1-axis pathways enhances anti-tumor efficacy by modulating immune cell infiltration and inducing immune activation. The immune activation signature resulting from combination therapy contributes to the enhanced anti-tumor activity.
Review
Immunology
Ye Han, Jiawei Sun, Hong Wei, Jiarong Hao, Weiyao Liu, Xiaolei Wang
Summary: Tumor immunotherapy has shown great potential in controlling and killing tumor cells, but current limitations hinder its efficacy. Ultrasound-target microbubble destruction (UTMD) treatment can reduce adverse events and improve drug penetration, leading to tumor cell death.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Yuan Gu, Maximilian A. Becker, Luisa Mueller, Katharina Reuss, Frederik Umlauf, Tianci Tang, Michael D. Menger, Matthias W. Laschke
Summary: Tumor endothelial cells (TECs) are crucial for tumor angiogenesis, growth and metastasis, and small non-coding microRNAs (miRNAs) play a significant role in regulating TEC function and blood vessel formation. This review provides an overview of the regulatory mechanisms and effects of endothelial miRNAs, highlighting their involvement in fundamental angiogenesis-related signaling pathways. Targeting endothelial miRNAs represents a potential strategy for anti-angiogenic cancer therapy, but further research is needed to understand their networks and develop specific delivery technologies.
Article
Oncology
Jack Lawler
Summary: Considerable progress has been made in understanding angiogenesis in normal and tumor tissue. The success of anti-angiogenic treatments has been limited so far, but it is expected to improve with the development of therapies targeting other pathways and a better understanding of resistance.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Menglu Zhang, Jiaqi Liu, Gang Liu, Zeyu Xing, Ziqi Jia, Jiaxin Li, Wenyan Wang, Jie Wang, Ling Qin, Xin Wang, Xiang Wang
Summary: Breast cancer, the highest incidence of female malignancy, is heavily reliant on neo-vascularization for growth and metastasis, with Vascular Endothelial Growth Factor (VEGF) playing a crucial role. This review focuses on the prognostic value of VEGF in breast cancer, clinical experiences with anti-VEGF therapeutics, and biomarkers for predicting the effectiveness of anti-angiogenic treatment.
Article
Chemistry, Multidisciplinary
Prashant Jain, Chethan D. Shanthamurthy, Shani Leviatan Ben-Arye, Sharon Yehuda, Sharvani S. Nandikol, Hirekodathakallu Thulasiram, Vered Padler-Karavani, Raghavendra Kikkeri
Summary: A potential heparan sulfate (HS) ligand was discovered to target several growth factors using specific HS tetrasaccharide ligands. One tetrasaccharide ligand showed strong binding with the VEGF(165) growth factor, and in vitro experiments demonstrated the therapeutic potential of these synthetic HS ligands by inhibiting vascular endothelial cell proliferation, migration, and angiogenesis in the presence of VEGF(165) and the specific tetrasaccharides.
CHEMICAL COMMUNICATIONS
(2021)
Article
Chemistry, Multidisciplinary
Yang Liu, Linyu Long, Fanjun Zhang, Xuefeng Hu, Jieyu Zhang, Cheng Hu, Yunbing Wang, Jianguo Xu
Summary: The study introduced a GelMA microneedle platform for sustained and controlled local delivery of AAV-VEGF, which achieved homogeneous distribution and high transfection efficiency in ischemic brains. Results showed that MNs loaded with AAV-VEGF increased VEGF expression in the brain cortex and enhanced functional angiogenesis and neurogenesis.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Immunology
Haein Huh, Ding-Wen Chen, Marianna Foldvari, Roderick Slavcev, Jonathan Blay
Summary: Colorectal cancer and other solid tumors in adults present challenges for successful treatment due to the tumor microenvironment hindering conventional therapies and suppressing immune activities. Genetic approaches have the potential to interfere with local immunosuppression, thereby facilitating immune responses against cancer. Bacterial phages provide a novel means of delivering targeted genetic interventions into tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Carlos Escudero, Jesenia Acurio, Eduardo Lopez, Andres Rodriguez, Antonia Benavente, Evelyn Lara, Steven J. Korzeniewski
Summary: Circulating VEGF levels were found to be elevated 24-48 hours after acute ischemic stroke and were associated with prognosis of moderate to severe disability at 6 months. Combining VEGF with interleukin 6 and C-reactive protein significantly improved predictive performance compared to using VEGF alone.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Zhiyang Li, Heng Zhang, Yujie Sun, Zhuangzhuang Feng, Bijia Cui, Jingxia Han, Yinan Li, Huijuan Liu, Tao Sun
Summary: Angiogenesis plays a crucial role in embryologic development, growth, and tissue repair, but dysregulation of this process is a hallmark of various pathologies, including cancer. Existing methods for evaluating cell vascular formation are often limited to static analysis, leading to bias. Researchers have developed code scripts to study the dynamic angiogenesis process, allowing for the screening of drugs that can affect various parameters of vascular formation. Animal experiments have confirmed the efficacy of these drugs in inhibiting blood vessel formation, providing a new perspective for angiogenesis research and drug development.
Review
Biochemistry & Molecular Biology
Mannon Geindreau, Francois Ghiringhelli, Melanie Bruchard
Summary: VEGF plays a crucial role in tumor growth by promoting angiogenesis and modulating the immune response. Clinical approval has been given to therapies targeting VEGF for the treatment of various cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Jing Liang, Shouqi Wang, Guowei Zhang, Baoyu He, Qingli Bie, Bin Zhang
Summary: Studying the differences, heterogeneity, and interaction of tumor-specific endothelial cells (TECs) with the tumor microenvironment is crucial for developing specific anti-tumor angiogenesis therapies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lawrence Kasherman, Ainhoa Madariaga, Marjan Rouzbahman, Kieran Murphy, David Shultz, Tracy Stockley, Amit M. Oza
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Lawrence Kasherman, Soha Ahrari, Stephanie Lheureux
Summary: Immune checkpoint inhibitors have shown significant clinical activity in various tumor subtypes, but their utility in gynecologic malignancies, particularly endometrial cancer, is still being explored. Dostarlimab, a PD-1 inhibitor, has demonstrated effectiveness and safety in recurrent EC, especially in the microsatellite instability-hypermutated/DNA mismatch repair deficient subgroup.
Review
Oncology
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K. Krzyzanowska
Summary: The study findings suggest that bevacizumab combination therapy can significantly improve progression-free survival (PFS) in advanced and recurrent epithelial ovarian cancer. In the first-line treatment, combining bevacizumab with chemotherapy showed significant PFS improvement compared to chemotherapy alone, but no significant benefit in overall survival (OS). However, in the recurrent setting, bevacizumab combinations demonstrated significant PFS and OS advantages.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Ainhoa Madariaga, Gita Bhat, Michelle K. Wilson, Xuan Li, Sunu Cyriac, Valerie Bowering, Wendy Hunt, David Gutierrez, Luisa Bonilla, Lawrence Kasherman, Michelle McMullen, Lisa Wang, Sangeet Ghai, Neesha C. Dhani, Amit M. Oza, Stephanie Lheureux
Summary: This study prospectively assessed the impact of research biopsies on the quality of life in patients with gynecologic cancer, as well as patient-reported outcomes and factors associated with willingness to undergo sequential biopsies. Results showed that research biopsies were generally well accepted, with most patients (83%) willing to undergo serial biopsies if necessary. Addressing modifiable psychosocial aspects of the procedure may improve the experience with research biopsies for patients with gynecologic cancers.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Review
Oncology
Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
Summary: The review explores the therapeutic potential of combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitor therapy in solid tumors, discussing scientific rationale, available clinical evidence, and considerations for future trial and biomarker development.
Editorial Material
Oncology
Ainhoa Madariaga, Lawrence Kasherman, Michelle McMullen, Luisa Bonilla
TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Lawrence Kasherman, Derrick Ho Wai Siu, Rachel Woodford, Carole A. Harris
Summary: In advanced kidney cancer, targeted or immune therapies have shown significant progress. However, the best treatment strategy and the resistance mechanisms are still unclear. This review article explores the scientific basis behind drug treatments for kidney cancer and summarizes the evidence supporting multi-drug treatments. Angiogenesis inhibitors have become the standard therapy for advanced-stage renal cell carcinomas, but combination regimens with immune checkpoint inhibitors have demonstrated better outcomes.
Review
Oncology
Won-Hee Yoon, Anna DeFazio, Lawrence Kasherman
Summary: Epithelial ovarian cancer (EOC) is highly lethal, and current advancements in immunotherapies have not shown the same success as in other gynecological malignancies. This review focuses on the ovarian tumor microenvironment and explores immunotherapeutic strategies, particularly in overcoming drug resistance.
CANCER DRUG RESISTANCE
(2023)
Meeting Abstract
Oncology
Lawrence Kasherman, Valerie Bowering, Xuan Li, Genevieve Bouchard-Fortier, Jennifer Croke, Jenny Lau, Rebecca Prince, Madeline Li, Amit Oza, Stephanie Lheureux
GYNECOLOGIC ONCOLOGY
(2021)
Meeting Abstract
Oncology
Ainhoa Madariaga, Gita Bhat, Xuan Li, Michelle Wilson, Sunu Cyriac, Valerie Bowering, Wendy Hunt, David Gutierrez, Luisa Bonilla, Lawrence Kasherman, Michelle McMullen, Lisa Wang, Sangeet Ghai, Neesha Dhani, Amit Oza, Stephanie Lheureux
GYNECOLOGIC ONCOLOGY
(2021)
Article
Obstetrics & Gynecology
Lawrence Kasherman, Swati Garg, Nairi Tchrakian, Blaise Clarke, Katherine Karakasis, Raymond H. Kim, Tracy L. Stockley, Neesha Dhani, Amit M. Oza, Stephanie Lheureux
GYNECOLOGIC ONCOLOGY REPORTS
(2021)
Review
Oncology
Lawrence Kasherman, Jeffrey Doi, Katherine Karakasis, Jeffrey Schiff, Abhijat Kitchlu, Stephanie Lheureux, Amit M. Oza
Summary: Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of malignancy, and treatment with angiogenesis inhibitors for advanced cancers in this context is not well-studied. This case presents a patient with recurrent high-grade serous ovarian carcinoma treated with paclitaxel and bevacizumab after renal transplantation, showing good response to treatment but also discussing the potential for increased adverse events and drug interactions in this specific population.
Review
Chemistry, Medicinal
Ainhoa Madariaga, Lawrence Kasherman, Katherine Karakasis, Pamela Degendorfer, Ann M. Heesters, Wei Xu, Shahid Husain, Amit M. Oza
Summary: Conducting clinical trials in public health emergencies presents unique challenges that require a coordinated and collaborative approach. Well-designed trials play a crucial role in discovering new diagnostic and management strategies.
MEDICINAL RESEARCH REVIEWS
(2021)
